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Résumé en
anglais
Vitamin K participates in brain physiology. This study aimed to determine whether
using vitamin K antagonists (VKAs), which interfere with the vitamin K cycle, were
(i) cross-sectionally associated with altered cognitive performance, and (ii)
independent predictors of cognitive changes in older adults over 24 months.
Information was collected on the use of VKAs (i.e., warfarin, acenocoumarol, and
fluindione) among 378 geriatric outpatients (mean, 82.3 ± 5.6 years; 60.1% female).
Global cognitive performance and executive functions were assessed with Mini-
Mental State Examination (MMSE) and Frontal Assessment Battery (FAB) scores,
respectively, at baseline and after 12 and 24 months of follow-up. Age, gender, body
mass index, mean arterial pressure, disability, gait speed, comorbidities, atrial
fibrillation, stroke, carotid artery stenosis, leukoaraiosis grade on computed
tomography (CT) scan, psychoactive drugs, antidementia drugs, blood-thinning
drugs (i.e., anticoagulants other than VKAs, antiplatelet medications), serum
creatinine levels, and vitamin B12 concentrations were considered as potential
confounders. Using VKAs was associated with lower (i.e., worse) FAB score at
baseline (adjusted β = -2.1, = 0.026), and with a decrease in FAB score after 24
months (adjusted β = -203.6%, = 0.010), but not after 12 months ( = 0.659). Using
VKAs was not associated with any change in MMSE score at baseline ( = 0.655),
after 12 months ( = 0.603), or after 24 months ( = 0.201). In conclusion, we found
more severe executive dysfunction at baseline and incident executive decline over
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